Novonesis and Novo Nordisk will explore new solutions to improve metabolic health

Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people.

COPENHAGEN, Denmark – September 8, 2025. Novonesis and Novo Nordisk has entered a research partnership to explore the role of the gut microbiome in the maintenance of metabolic health. The gut microbiome is the collection of microorganisms, such as bacteria, fungi, and viruses, that naturally live in the human gut. The science surrounding the microbiome, and how it contributes to human health in many ways, has grown tremendously over the last years¹.

Novonesis and Novo Nordisk will work closely to explore solutions that seek to preserve and optimize metabolic health and improve people’s well-being mediated through the gut microbiome. Synbiotic food supplements, composed of probiotics and prebiotics, will be developed and tested for their ability to affect health parameters linked to metabolic health such as blood glucose and cholesterol levels. Probiotics are living microorganisms, while prebiotics are the “fuel” that helps sustain these beneficial microorganisms.²

The partnership will investigate how the gut microbiome may be used to monitor and predict metabolic and overall health trajectories in individuals. Additionally, it will explore novel biomarkers with the aim of measuring the effectiveness of gut microbiome solutions.

“At Novonesis, we are committed to advancing our understanding of the human microbiome and the crucial role it plays in digestion, immunity, mood, well-being, and much more. This new collaboration with Novo Nordisk enables us to deepen our understanding of the gut microbiome’s role in maintaining metabolic health and to identify innovative products that support it. Together, we will conduct research on the gut microbiome for predictive purposes and strive to create impactful biosolutions that enhance health and well-being throughout life stages”, says Henrik Joerck Nielsen, Executive Vice President, Human Health Biosolutions & Strategy.

Obesity is recognized as a chronic, progressive disease by the World Health Organization (WHO).³ It is a multifactorial disease that is associated with more than 200 possible health complications, including type 2 diabetes and cardiovascular disease.⁴

“Obesity is a complex disease driven by multiple factors, including our hormones and genetics, and we are becoming increasingly aware of the role the gut plays in maintaining metabolic health and thereby minimizing the risk of developing obesity,⁵” says Professor Nadeem Sarwar, Corporate Vice President and Head of the Transformational Prevention Unit in Obesity at Novo Nordisk.